CN108815448A - A kind of Chinese herbal granules for treating chronic colitis - Google Patents
A kind of Chinese herbal granules for treating chronic colitis Download PDFInfo
- Publication number
- CN108815448A CN108815448A CN201810782877.9A CN201810782877A CN108815448A CN 108815448 A CN108815448 A CN 108815448A CN 201810782877 A CN201810782877 A CN 201810782877A CN 108815448 A CN108815448 A CN 108815448A
- Authority
- CN
- China
- Prior art keywords
- parts
- chronic colitis
- treatment
- chinese herbal
- colitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000001684 chronic effect Effects 0.000 title claims abstract description 52
- 206010009887 colitis Diseases 0.000 title claims abstract description 40
- 239000008187 granular material Substances 0.000 title claims abstract description 28
- 239000003814 drug Substances 0.000 claims abstract description 44
- 229940079593 drug Drugs 0.000 claims abstract description 29
- 238000002360 preparation method Methods 0.000 claims abstract description 20
- 244000247747 Coptis groenlandica Species 0.000 claims description 17
- 235000002991 Coptis groenlandica Nutrition 0.000 claims description 17
- 240000002943 Elettaria cardamomum Species 0.000 claims description 16
- 235000005300 cardamomo Nutrition 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 239000002245 particle Substances 0.000 claims description 15
- 239000000463 material Substances 0.000 claims description 14
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims description 13
- 241000756943 Codonopsis Species 0.000 claims description 10
- 235000019441 ethanol Nutrition 0.000 claims description 9
- 239000002994 raw material Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000000853 adhesive Substances 0.000 claims description 6
- 230000001070 adhesive effect Effects 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000011084 recovery Methods 0.000 claims description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 230000006837 decompression Effects 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 230000002572 peristaltic effect Effects 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 230000002829 reductive effect Effects 0.000 claims description 3
- 238000005507 spraying Methods 0.000 claims description 3
- 235000013402 health food Nutrition 0.000 claims description 2
- 239000006199 nebulizer Substances 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 238000004821 distillation Methods 0.000 claims 1
- 238000005243 fluidization Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract description 13
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract description 13
- 238000000034 method Methods 0.000 abstract description 9
- 206010067484 Adverse reaction Diseases 0.000 abstract description 5
- 230000006838 adverse reaction Effects 0.000 abstract description 5
- 238000010171 animal model Methods 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 3
- 238000002474 experimental method Methods 0.000 abstract description 3
- 230000003285 pharmacodynamic effect Effects 0.000 abstract description 3
- 238000011160 research Methods 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 239000003390 Chinese drug Substances 0.000 abstract description 2
- 239000002547 new drug Substances 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 25
- 206010012735 Diarrhoea Diseases 0.000 description 15
- 210000001072 colon Anatomy 0.000 description 15
- 230000000694 effects Effects 0.000 description 13
- 208000025865 Ulcer Diseases 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 238000011552 rat model Methods 0.000 description 9
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 8
- 208000035861 hematochezia Diseases 0.000 description 8
- 231100000397 ulcer Toxicity 0.000 description 8
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 241000208340 Araliaceae Species 0.000 description 6
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 6
- 235000003140 Panax quinquefolius Nutrition 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 235000008434 ginseng Nutrition 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000000341 volatile oil Substances 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000000472 traumatic effect Effects 0.000 description 3
- WITLAWYGGVAFLU-UHFFFAOYSA-N 3-(6-methoxy-1,3-benzodioxol-5-yl)-8,8-dimethylpyrano[2,3-f]chromen-4-one Chemical compound C1=CC(C)(C)OC2=CC=C(C(C(C3=CC=4OCOC=4C=C3OC)=CO3)=O)C3=C21 WITLAWYGGVAFLU-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000001142 anti-diarrhea Effects 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 239000003212 astringent agent Substances 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 230000036269 ulceration Effects 0.000 description 2
- ZTVSGQPHMUYCRS-SWLSCSKDSA-N (4as,8as)-3,8a-dimethyl-5-methylidene-4a,6,7,8-tetrahydro-4h-benzo[f][1]benzofuran-2-one Chemical compound C=C([C@@H]1C2)CCC[C@]1(C)C=C1C2=C(C)C(=O)O1 ZTVSGQPHMUYCRS-SWLSCSKDSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000084 Abdominal pain lower Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- OQYBLUDOOFOBPO-UHFFFAOYSA-N Asterolide Natural products C1C2C(=C)CCCC2(C)CC2C1=C(C)C(=O)O2 OQYBLUDOOFOBPO-UHFFFAOYSA-N 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- NBSRUZQXRUNPNY-FOCLMDBBSA-N NS(=O)(=O)c1ccc(cc1)\N=N\c1ccc(O)c(c1)C(O)=O Chemical compound NS(=O)(=O)c1ccc(cc1)\N=N\c1ccc(O)c(c1)C(O)=O NBSRUZQXRUNPNY-FOCLMDBBSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 206010051986 Pneumatosis Diseases 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 206010057071 Rectal tenesmus Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 206010042220 Stress ulcer Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 210000004953 colonic tissue Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 208000016290 incoordination Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000036445 liquid secretion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 229950008351 salazosulfamide Drugs 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000001599 sigmoid colon Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 208000012271 tenesmus Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/238—Saposhnikovia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9064—Amomum, e.g. round cardamom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to pharmaceutical technology field, the Chinese herbal granules of specifically a kind for the treatment of chronic colitis and application.The present invention shows there is significant therapeutic effect for chronic ulcerative colitis animal model through pharmacodynamic experiment；The present invention is significant in efficacy in the treatment for being clinically used for chronic colitis, and has no serious adverse reaction, securely and reliably；The present invention will provide a kind of new active drug for the treatment of the traditional Chinese medicine of chronic colitis, enrich the research contents of pharmaceutics of Chinese drugs, and convert providing method to new drug for Chinese medicine hospital preparation and use for reference.
Description
Technical field
The present invention relates to pharmaceutical technology fields, specifically, be a kind of Chinese herbal granules for treating chronic colitis and its
Preparation method and application.
Background technique
Chronic colitis is a kind of common multiple using colon, sigmoid colon and rectum as the enteron aisle disease of site of pathological change
Disease, the cardinal symptom of the disease be left lower quadrant pain, diarrhea, it is tenesmus, when just descend mucus, constipation or diarrhea alternately to occur, when
It is bad when good.According to statistics, the disease incidence of nearly 10 years China's chronic colitis increases 10 times compared with the fifties in last century, it has also become clinical
One of common disease and frequently-occurring disease.Currently, western medical treatment chronic colitis is suitable only for short-term medication；If long term administration, can also draw
Play a variety of adverse reactions such as serious gastrointestinal reaction, hemopoietic function of bone marrow inhibition, allergy.Therefore, it is sought from Chinese Traditional Medicine
Novel anti-chronic colitis drug is looked for and developed with good development potentiality and important scientific value.Chronic colitis according to
Its typical clinical manifestations, clinical treatment should with eliminating dampnessization it is turbid with temporary solution, invigorating the spleen peace in antidiarrheal with reinforcing be main therapy.
Summary of the invention
The purpose of the present invention is to provide a kind of Chinese herbal granules and its preparation method and application for treating chronic colitis.
A kind of Chinese herbal granules for treating chronic colitis of the invention are the characteristic formulations for treating chronic colitis, by
Rhizoma Atractylodis Macrocephalae, Radix Codonopsis, Amomum cardamomum, the coptis, radix saposhnikoviae, dark plum, 7 taste medicine of red halloysite composition.We system is according to chronic colitis " Spleen-Qi Deficiency
The Chinese medicine core interpretation of the cause, onset and process of an illness of weak, wet accumulateing heat, wave blood and liver " selects to have strengthening the spleen and replenishing qi, heat-clearing and damp-drying drug, purging the liver of pathogenic fire relieving haperacidity effect
Rhizoma Atractylodis Macrocephalae is monarch drug in a prescription；Radix Codonopsis function help spleen and lung in side, Amomum cardamomum function dampness elimination promoting the circulation of qi, for treat retention of damp leading to blockage of QI, it is incoordination between the spleen and the stomach it
Key medicine, Papillary, replenish qi to invigorate the spleen Zhi Qiben, its mark is controlled in promoting the circulation of qi dampness elimination, and principal drug assistance invigorating spleen to remove dampness antidiarrheal is altogether ministerial drug.The coptis
Heat-clearing and damp-drying drug, thick intestines stop benefit, and radix saposhnikoviae expels pathogenic wind from the body surface, and expel endogenous wind to relieve convulsion, dark plum relieving diarrhea with astringents cures mainly protracted dysentery and diarrhea, is altogether adjutant；It is red
Mountain tallow priming enters large intestine, with to make medicine.All medicines share plays strengthening the spleen and replenishing qi, dampness removing heat-clearing, the function of relieving diarrhea with astringents altogether.
The modern study of the party is confirmed：Rhizoma Atractylodis Macrocephalae mainly contains volatile oil and polysaccharide component, wherein interior in volatile oil
Lactone component has anti-inflammatory, adjusting immunization, and has effects that improve gastrointestinal function and promote absorption of nutrient ingredients, especially
It is significant with atractylenolide Ⅰ effect.Meanwhile Rhizoma Atractylodis Macrocephalae can promote the proliferation of gastric mucosal cell, stimulate the secretion of pepsin, and corresponding
Stress ulcer has very strong preventive effect.Radix Codonopsis has containing ingredients such as various saccharides, phenols, sterol, saponin and Alkaloids
Strengthen immunity improves the effects of microcirculation, enhancing hematopoiesis function.Amomum cardamomum volatile oil component containing there are many, can promote stomach
Liquid secretion, enhances gastrointestinal peristalsis, prevents enteral abnormal fermentation, dispels gastrointestinal pneumatosis, there is good fragrant digestion promoting function.In the coptis
The composition of alkaloids such as jamaicin have that antibacterial, anti-inflammatory, to inhibit platelet aggregation, hypoglycemic and anti-arrhythmia etc. extensive
Pharmacological activity.There is significant inhibiting effect for the colitis in mice induced dextran sulfuric acid, it can agent
The mitigation mouse colitis symptom for measuring dependence checks colonic mucosa pathological change, reduces colonic tissue MDA content, increases MPO
Vigor and SOD activity, curative effect are suitable with salicylazosulfapyridine.Radix saposhnikoviae mainly contain volatile oil, chromogen ketone, Coumarins,
The ingredients such as polysaccharide, extract have the effects that antibacterial, anti-inflammatory, antiallergy, hemostasis and immunological regulation, the organic acid in dark plum
Ingredient has apparent antibacterial, anti-allergic effects, these components are for diseases such as bleeding caused by chronic colitis, abdominal pain, diarrhea
Shape all has good inhibiting effect.Party's prescription is comprehensive, and compatibility is reasonable, for the chronic colon of obstinate, recurrent exerbation
Scorching patient has significant therapeutic effect.Each specific modern pharmacy result of study of drug is using Modern preparations technique in prescription
The party is prepared into meet the modern life needs new compound Chinese medicinal preparation provide solid test basis.
For the Chinese herbal granules dose big (20g/ times, 3 times a day) for the treatment of chronic colitis of the invention, containing big
Sugar is measured, is not suitable for the disadvantages of special populations such as diabetes needs, existing quality standard are coarse, and preparation stability is poor, uses
Modern preparations technique is developed into and takes the adaptation modern lives such as easy to carry, applied widely, stability is good and society's hair
Six kind new medicine of Chinese medicine needed is opened up, will have good social benefit and economic benefit.
The first aspect of the present invention provides a kind of Chinese herbal granules for treating chronic colitis, by the original of following parts by weight
Material medicine is made：It is 150-200 parts of Rhizoma Atractylodis Macrocephalae, 100-120 parts of Radix Codonopsis, 90-120 parts of Amomum cardamomum, 75-100 parts of the coptis, 60-90 parts windproof,
75-100 parts of dark plum, 200-240 parts of red halloysite.
Further, the preparation method of the Chinese herbal granules of the treatment chronic colitis, includes the following steps：
(A) raw extract dry extract is broken to fine powder, sieves with 100 mesh sieve, and lactose and dry extract are put in fluidized bed
In fluidising chamber, boiled by adjusting air quantity to material；
(B) material can start spraying after preheating, after the temperature of material reaches 40 DEG C, open atomizer, select dense
Degree is that 5% HPMC makees adhesive, and nebulizer pressure is adjusted to 0.1MPa, and adhesive is then sprayed into fluidising chamber, is made
Grain；
(C) revolving speed for adjusting blower is 1700rpm, and the temperature of air inlet is 65 DEG C, the speed of peristaltic pump charging is 4 → 6 →
8HZ；
(D) after grain forming, need to continue to be dried with 50 DEG C of hot wind, after general 0.5 hour, take out particle into
Particle is crossed No. 1 sieve and No. 5 sieves respectively by row weighing, and No. 1 sieve can be crossed but cannot cross No. 5 sieves by finally carrying out finishing collecting
Particle dispenses to obtain the final product.
Further, the preparation method of raw extract dry extract described in step (A), includes the following steps：
A, Rhizoma Atractylodis Macrocephalae, Radix Codonopsis, Amomum cardamomum, the coptis, radix saposhnikoviae, dark plum are weighed according to the ratio, and red halloysite is added 10 times of medicinal material weight
Distilled water decocts, and decocts number 2 times, and decocting time is each 1h；
B, decoction liquor is filtered, it is 1 that filtrate, which is concentrated into 90-95 DEG C of relative density,：1.08~1.10, room temperature to be cooled to is added
95% ethyl alcohol adjusts alcohol precipitation concentration to 70%；
C, 24 hours are stood for 4 DEG C, filtration, filtrate decompression concentration and recovery ethyl alcohol, being condensed into 50-60 DEG C of relative density is 1：
1.25-1.30 medicinal extract；
D, it is dried under reduced pressure under 60 DEG C, 1Mpa again, obtains extract dry extract.
The second aspect of the present invention, the Chinese herbal granules for providing a kind for the treatment of chronic colitis as described above are pre- in preparation
Application in anti-or treatment chronic colitis drug or health food.
The invention has the advantages that：
1, the present invention shows there is significant treatment effect for chronic ulcerative colitis animal model through pharmacodynamic experiment
Fruit.Through clinical test, the effective percentage for treating chronic ulcerative colitis is 95%, treats the effective of chronic non-ulcerative colitis
Rate is 90%, has significant statistical difference compared with the control group；
2, the present invention is significant in efficacy in the treatment for being clinically used for chronic colitis, and has no serious adverse reaction, peace
It is complete reliable；
3, the present invention will provide a kind of new active drug for the treatment of the traditional Chinese medicine of chronic colitis, enrich pharmaceutics of Chinese drugs
Research contents, and for Chinese medicine hospital preparation to new drug convert providing method use for reference.
Specific embodiment
It elaborates below with reference to embodiment to specific embodiment provided by the invention.
Embodiment 1：
A kind of Chinese herbal granules for treating chronic colitis, are prepared from the following raw materials in parts by weight：150 parts of Rhizoma Atractylodis Macrocephalae, party
100 parts of ginseng, 90 parts of Amomum cardamomum, 75 parts of the coptis, 60 parts, 75 parts of dark plum, 200 parts of red halloysite of radix saposhnikoviae.
Embodiment 2：
A kind of Chinese herbal granules for treating chronic colitis, are prepared from the following raw materials in parts by weight：200 parts of Rhizoma Atractylodis Macrocephalae, party
120 parts of ginseng, 120 parts of Amomum cardamomum, 100 parts of the coptis, 90 parts, 100 parts of dark plum, 240 parts of red halloysite of radix saposhnikoviae.
Embodiment 3：
A kind of Chinese herbal granules for treating chronic colitis, are prepared from the following raw materials in parts by weight：160 parts of Rhizoma Atractylodis Macrocephalae, party
105 parts of ginseng, 95 parts of Amomum cardamomum, 80 parts of the coptis, 65 parts, 80 parts of dark plum, 210 parts of red halloysite of radix saposhnikoviae.
Embodiment 4：
A kind of Chinese herbal granules for treating chronic colitis, are prepared from the following raw materials in parts by weight：170 parts of Rhizoma Atractylodis Macrocephalae, party
110 parts of ginseng, 100 parts of Amomum cardamomum, 85 parts of the coptis, 70 parts, 85 parts of dark plum, 220 parts of red halloysite of radix saposhnikoviae.
Embodiment 5：
A kind of Chinese herbal granules for treating chronic colitis, are prepared from the following raw materials in parts by weight：180 parts of Rhizoma Atractylodis Macrocephalae, party
115 parts of ginseng, 110 parts of Amomum cardamomum, 90 parts of the coptis, 75 parts, 90 parts of dark plum, 230 parts of red halloysite of radix saposhnikoviae.
Embodiment 6：
A kind of Chinese herbal granules for treating chronic colitis, are prepared from the following raw materials in parts by weight：190 parts of Rhizoma Atractylodis Macrocephalae, party
118 parts of ginseng, 115 parts of Amomum cardamomum, 95 parts of the coptis, 80 parts, 95 parts of dark plum, 225 parts of red halloysite of radix saposhnikoviae.
Embodiment 7：Chinese medicinal compound extract of the invention
Weigh Rhizoma Atractylodis Macrocephalae 300g, Radix Codonopsis 200g, Amomum cardamomum 180g, the coptis 150g, windproof 120g, dark plum 150g, red halloysite
The water that 10 times of amounts are added in 400g decocts 2 times, and decocting time is 1 hour every time, merges decoction liquor, filtration, and filtrate is concentrated into relatively
Density is 1: 1.08~1.10 (90-95 DEG C), room temperature to be cooled to, be added 95% ethyl alcohol adjust solution determining alcohol to 70%, 4 DEG C it is quiet
It sets 24 hours, filters, filtrate decompression concentration and recovery ethyl alcohol, be condensed into the leaching that relative density is 1: 1.25-1.30 (50-60 DEG C)
Cream, then be dried under reduced pressure under 60 DEG C, 1Mpa, obtain extract dry extract.
Embodiment 8：The preparation of granule of the invention
The resulting extract dry extract extract dry extract of embodiment 7 is broken to fine powder, is sieved with 100 mesh sieve, 20g cream is weighed
Sugar and 200g dry extract are put in the fluidising chamber of fluidized bed, are boiled by adjusting air quantity to material.It can be opened after material preheating
It is dynamic spraying, i.e., after the temperature of material reaches 40 DEG C, atomizer is opened, selecting mass concentration is that 5% HPMC makees adhesive, is atomized
Device pressure is adjusted to 0.1MPa, is sprayed into adhesive granulation to fluidising chamber, is pelletized.Speed-frequency blower is straight by adjusting
To 1700rpm, the temperature of air inlet is set as 65 DEG C, and the speed of peristaltic pump is set as 4 → 6 → 8Hz, and (each speed keeps adjusting for 10 minutes
It is whole to arrive next revolving speed, remain unchanged after reaching maximum speed to preparation completion).After grain forming, need to continue with 50 DEG C
Hot wind is dried, and after general 0.5 hour, takes out particle and weighs, and particle is crossed No. 1 sieve and No. 5 sieves respectively, is finally carried out
Finishing collecting can cross No. 1 sieve but cannot cross the particle of No. 5 sieves.It dispenses to obtain the final product.
Embodiment 9：Clinical test
The granule prepared using embodiment 8 is treated patients with chronic colitis 60, observes its validity and safety.
Wherein, male 36, female 24, is randomly divided into 3 groups, i.e. chronic ulcerative colitis treatment group, chronic non-ulcerative colitis is controlled
Treatment group and control group, every group of 20 people.The Chinese medicinal compound extract prepared in Liang Ge treatment group patients received oral's embodiment of the present invention 8
Granule, granular preparation used in control group are blank granules preparation, that is, Chinese medicinal compound extract ingredient are free of, with same ratio
Lactose and dextrin be added burnt sugar coloring edible coloring agent particle is made to the granular preparation identical appearance prepared with embodiment 8 and mouth
Sense, oral administration, 2 times a day, and each 6g, medication course 8 weeks.Overall evaluation patient's recovery situation is divided into effective, improvement, nothing
Imitate 3 levels.It the results are shown in Table 1.
Table 1, which treats 8 weeks general curative effects, improves evaluation table
It is efficient：(effective number of cases+improvement number of cases)/all cases number × 100%
By treatment in 8 weeks, the effective percentage for treating chronic ulcerative colitis was 95%, treated chronic non-ulcerative colon
Scorching effective percentage is 90%, and the effective percentage of control group is 25%, and treatment group will be substantially better than control group.
3 mild nauseas, abdominal distension or discomfort occur altogether for Liang Ge treatment group, and control group has no adverse reaction, phase between group
Than no difference of science of statistics, show the good security of granule of the invention.
The experiment of 10 prescription compatibility dose study of embodiment
The compatibility of drugs dosage of prescription of the present invention is screened using pharmacodynamic study method.
1. experimental animal
Healthy male SD rat, cleaning grade, weight are purchased from The 2nd Army Medical College Experimental Animal Center in 180g~200g
(animal certificate number：SCXK2017-0003), free water and feed.
2. reagent
Take respectively the embodiment of the present invention 1, embodiment 2,3 compatibility dosage of embodiment Chinese medicine material medicine, by embodiment 7-8's
Medicinal material extract technique, Preparation Technology of Granules prepare the test sample 1 that prescription number is 1-3, sample 2, sample 3, carry out medicine
Effect learns research.
3. the foundation of animal packet and chronic ulcerative colitis rat model
Male SD rat 60 are taken, 6 groups, i.e. Normal group, model group, positive control drug Salazosulfamide arsenic are randomly divided into
Pyridine group, sample 1, sample 2,3 groups of sample, every group 10.After being deprived of food but not water for 24 hours, in addition to Normal group, remaining each group rat
2% carbrital is injected intraperitoneally in modeling, and after making rat light anaesthesia, the emulsion tube per anum of diameter 2mm is gently inserted into
In rat body at about 8cm, modeling agent TNBS is dissolved in 50% ethanol water, TNBS solution is disposably injected with syringe
Into the enteric cavity of rat, TNBS dosage is to lift the tail portion of rat by weight 100mg/kg, is inverted 30 seconds, prevents modeling agent
Leakage, make modeling agent it is fully penetrated enter rat enteric cavity.
4. medication and evaluation index
6h starts to be administered after modeling, once a day, successive administration 10d.Administration group distinguishes daily gastric infusion 2ml；Normally
The physiological saline of control group and the daily stomach-filling same volume of model group rats.Different sample sets are observed respectively to chronic ulcerative colon
The influence of scorching rat model changes of weight, diarrhea, hematochezia.
After 10d is administered in each group rat, injection overdose of sodium pentobarbital is lethal, splits rat abdomen, observes the big structural reform of enteron aisle
Become.Latter end colon away from anus 10cm long is taken out, is blotted with ice normal saline flushing with filter paper along mesenterium longitudinal incision
Claim quality after moisture.Mucous membrane is unfolded upwardly, mucosa injury and the scoring mark according to Wallace and Keenan1990 are observed
Standard scores：0 point, no inflammation and ulcer；1 point, contrafluxion but without ulcer；2 points, ulcer but without hyperemia；It 3 points, bursts at one
Ulcer and inflammation；4 points, the above ulcer and inflammation at two or at two；5 points, ulcer extends beyond 2cm.
5. experimental result
Influence of the 5.1 different ratio sample particles to chronic ulcerative colitis rat model changes of weight
For rats in normal control group due to fasting 1d, weight is gradually restored to original weight after slightly mitigating, and gradually increases
Add to the 115% of substance weight.The weight of TNBS model group rats declines rapidly after modeling, drops to original weight in 2d
86%, weight is substantially less than normal rats weight (P in 1~7d<0.05), in 3 groups of samples, sample 1, sample 3 and the positive
Control rats weight recovery is very fast, and 5~6d is gradually restored to original weight, and the weight of rat is significantly higher than mould in 1~7d
Type rat (P<0.05).
Influence of the 5.2 different ratio sample particles to chronic ulcerative colitis rat model diarrhea and hematochezia
Diarrhea occurs in 1,3,5,7d for each group rat and the rat number of hematochezia is shown in Table 2.Rats in normal control group does not have
Occur diarrhea and hematochezia, the rat after TNBS modeling shows as that hair color is matt in a jumble, and look burnout is dispirited, occurs in 1d
Different degrees of diarrhea and hematochezia.But diarrhea occurs in 7d for model group rats and the number of hematochezia is significantly more than sample sets
And positive controls.Illustrate that 3 groups of samples and positive control drug are inhibited to the diarrhea and hematochezia of rat model, wherein sample
1 group of effect of product and positive control drug are suitable.
Influence (n=10) of 2 sample particle of table to chronic ulcerative colitis rat model diarrhea and hematochezia
The influence that 5.3 sample particles score to chronic ulcerative colitis rat model Traumatic Colon
Colon appearance and mucous membrane surface discovery, the colon majority and adjacent internal organs of model group rats are observed after rat is dissected
There is slight adhesion, colon congestion and edema has biggish exedens lesion, affected area colon wall thickening, intestines at the upward 8cm of anus mouth
Curing ulcer erosion necrosis occurs for mucous membrane surface, and compared with normal rats, colon obviously shortens.3 groups of samples and positive controls are equal
The inflammatory symptoms such as colon congestion and edema can be improved, reduce ulcer area, mitigate colon weight, reduce rat model Traumatic Colon
Score (P<0.05) 3, be the results are shown in Table.
The influence that 3 sample particle of table scores to chronic ulcerative colitis rat model Traumatic Colon
* P < 0.05vs TNBS model group；* P < 0.01vs TNBS model group
Result of study shows that sample 1 (embodiment 1) has optimal drug action, suitable with positive control drug.
11 clinical observation of embodiment
In order to further investigate the clinical application effect of prescription compatibility of the present invention, we are by medicament composing prescription of the present invention and document
Report that prescription carries out Comparison of clinical effect observation.
1, method
Test group drug composition：Rhizoma Atractylodis Macrocephalae 30g, Radix Codonopsis 20g, Amomum cardamomum 18g, the coptis 15g, windproof 12g, dark plum 15g, red stone
Rouge 40g；
Control group drug composition：Rhizoma Atractylodis Macrocephalae 30g, the coptis 15g, windproof 12g, dark plum 15g.
Water decocts two groups of prescriptions according to a conventional method, oral administration.
Patients with chronic colitis 60 are chosen, wherein male 32, are randomly divided into two groups, respectively test by women 28
Group and control group.Two groups of patients distinguish oral test group drug and control group drug decocting liquid, each primary daily morning and evening, continuous to take
With after a week, deactivate one day.The clinical effectiveness and adverse reaction rate of two groups of drugs are investigated in medication after 8 weeks.
2, result
Two groups of drugs have good therapeutic effect to patients with chronic colitis, and the effective percentage of test group is 93.4%,
The effective percentage of control group is 86.6%.Test group has 1 patient slight physogastry occur；Control group has 2 patients to dislike
There is symptom of diarrhea in the heart, 2 patients.Test group adverse reaction rate (3.33%) is lower than control group (13.3%).
Table 4, which treats 8 weeks general curative effects, improves evaluation table
Effective percentage=(effective number of cases+improvement number of cases)/all cases number × 100%.
The preferred embodiment of the present invention has been described in detail above, but the invention be not limited to it is described
Embodiment, those skilled in the art can also make various equivalent on the premise of not violating the inventive spirit of the present invention
Variation or replacement, these equivalent variation or replacement are all included in the scope defined by the claims of the present application.
Claims (5)
1. a kind of Chinese herbal granules for treating chronic colitis, which is characterized in that be prepared from the following raw materials in parts by weight：Rhizoma Atractylodis Macrocephalae
It is 150-200 parts, 100-120 parts of Radix Codonopsis, 90-120 parts of Amomum cardamomum, 75-100 parts of the coptis, 60-90 parts windproof, 75-100 parts of dark plum,
200-240 parts of red halloysite.
2. the Chinese herbal granules for the treatment of chronic colitis according to claim 1, which is characterized in that by following parts by weight
Bulk pharmaceutical chemicals are made：150 parts of Rhizoma Atractylodis Macrocephalae, 100 parts of Radix Codonopsis, 90 parts of Amomum cardamomum, 75 parts of the coptis, 60 parts of radix saposhnikoviae, 75 parts of dark plum, red halloysite
200 parts.
3. the Chinese herbal granules for the treatment of chronic colitis according to claim 1, which is characterized in that the granule
Preparation method includes the following steps：
(A) raw extract dry extract is broken to fine powder, sieves with 100 mesh sieve, and lactose and dry extract are put in the fluidisation of fluidized bed
In room, boiled by adjusting air quantity to material；
(B) material can start spraying after preheating, after the temperature of material reaches 40 DEG C, open atomizer, and concentration is selected to be
5% HPMC makees adhesive, and nebulizer pressure is adjusted to 0.1MPa, and adhesive is then sprayed into fluidising chamber, is pelletized；
(C) revolving speed for adjusting blower is 1700rpm, and the temperature of air inlet is 65 DEG C, and the speed of peristaltic pump charging is 4 → 6 → 8HZ；
(D) it after grain forming, needs to continue to be dried with 50 DEG C of hot wind, after general 0.5 hour, takes out particle and claimed
Particle is crossed No. 1 sieve and No. 5 sieves respectively by weight, and No. 1 sieve can be crossed but cannot cross the particle of No. 5 sieves by finally carrying out finishing collecting,
It dispenses to obtain the final product.
4. the Chinese herbal granules for the treatment of chronic colitis according to claim 3, which is characterized in that original described in step A
The preparation method for expecting extract dry extract, includes the following steps：
A, Rhizoma Atractylodis Macrocephalae, Radix Codonopsis, Amomum cardamomum, the coptis, radix saposhnikoviae, dark plum are weighed according to the ratio, and 10 times of medicinal material weight of distillation is added in red halloysite
Water decocts, and decocts number 2 times, and decocting time is each 1h；
B, decoction liquor is filtered, it is 1 that filtrate, which is concentrated into 90-95 DEG C of relative density,：1.08~1.10, room temperature to be cooled to is added 95%
Ethyl alcohol adjusts alcohol precipitation concentration to 70%；
C, 24 hours are stood for 4 DEG C, filtration, filtrate decompression concentration and recovery ethyl alcohol, being condensed into 50-60 DEG C of relative density is 1：1.25-
1.30 medicinal extract；
D, it is dried under reduced pressure under 60 DEG C, 1Mpa again, obtains extract dry extract.
5. a kind of Chinese herbal granules of the treatment chronic colitis as described in claim 1-4 is any are slow in preparation prevention or treatment
Application in property colitis drug or health food.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810782877.9A CN108815448B (en) | 2018-07-17 | 2018-07-17 | Traditional Chinese medicine granules for treating chronic colitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810782877.9A CN108815448B (en) | 2018-07-17 | 2018-07-17 | Traditional Chinese medicine granules for treating chronic colitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108815448A true CN108815448A (en) | 2018-11-16 |
| CN108815448B CN108815448B (en) | 2021-04-30 |
Family
ID=64140646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810782877.9A Active CN108815448B (en) | 2018-07-17 | 2018-07-17 | Traditional Chinese medicine granules for treating chronic colitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108815448B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111494403A (en) * | 2019-01-31 | 2020-08-07 | 成都中医药大学 | Application of atractylodes macrocephala polysaccharide in preparing medicine for preventing and treating ulcerative colitis |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102085252A (en) * | 2011-01-21 | 2011-06-08 | 中国人民解放军第二军医大学 | Pharmaceutical composition for treating ulcerative colitis and colon-targeted micro-pill preparation thereof |
| CN103784848A (en) * | 2014-01-15 | 2014-05-14 | 中国人民解放军第二军医大学 | Traditional Chinese medicinal composition for treating chronic colitis and preparation and application thereof |
-
2018
- 2018-07-17 CN CN201810782877.9A patent/CN108815448B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102085252A (en) * | 2011-01-21 | 2011-06-08 | 中国人民解放军第二军医大学 | Pharmaceutical composition for treating ulcerative colitis and colon-targeted micro-pill preparation thereof |
| CN103784848A (en) * | 2014-01-15 | 2014-05-14 | 中国人民解放军第二军医大学 | Traditional Chinese medicinal composition for treating chronic colitis and preparation and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 邵雪庆等: "用流化制粒技术制备的愈肠颗粒的药效学研究", 《药学服务与研究》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111494403A (en) * | 2019-01-31 | 2020-08-07 | 成都中医药大学 | Application of atractylodes macrocephala polysaccharide in preparing medicine for preventing and treating ulcerative colitis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108815448B (en) | 2021-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104873947A (en) | Medicinal composition for treating dog acute upper gastrointestinal hemorrhage and preparation method thereof | |
| CN104173969A (en) | Traditional Chinese medicine preparation for treating chronic gastritis caused by deficient cold of spleen and stomach and preparation method thereof | |
| CN103495040A (en) | Traditional Chinese medicine composition for treating reflux esophagitis and preparation method of granule formulation thereof | |
| CN105250821B (en) | A kind of compound Chinese medicinal preparation and preparation method thereof for treating ulcerative colitis | |
| CN111388587A (en) | Traditional Chinese medicine composition for preparing medicine for treating functional dyspepsia | |
| CN108619355A (en) | A kind of antitumor Chinese and preparation method thereof | |
| CN110772564A (en) | Traditional Chinese medicine extract composition with depression mood regulating effect, preparation method thereof and traditional Chinese medicine preparation | |
| CN108815448A (en) | A kind of Chinese herbal granules for treating chronic colitis | |
| CN102028865A (en) | Medicinal composition for relieving cough and reducing sputum and method for preparing same | |
| CN114712478B (en) | Traditional Chinese medicine composition for treating intestinal diseases, preparation and preparation method thereof | |
| CN100509041C (en) | Stomach-clearing pill | |
| CN1712055A (en) | Chinese medicinal preparation (litholytic capsule) for treating urinific calculus | |
| CN102949572A (en) | Medicinal composition for treating throat diseases, and its preparation method | |
| CN1220517C (en) | Medication for curing disease of stomach intestine | |
| CN102274428B (en) | Pharmaceutical composition with effect on treating irritable bowel syndrome and preparation method and application thereof | |
| CN1903347A (en) | Medicine composition for treating alimentary canal diseases, prepn. method and application thereof | |
| CN106563076B (en) | Medicine for treating stomach disease and its preparing method | |
| CN104906472A (en) | Traditional Chinese medicine composition for preventing and treating cough-variant asthma | |
| CN116440224B (en) | Traditional Chinese medicine composition, preparation and preparation method | |
| CN102885915B (en) | Preparation method of controlled-release capsule with functions of detoxifying and diarrhea stopping | |
| CN101167915B (en) | Traditional Chinese medicine for treating chronic superficial gastritis and its preparation method | |
| CN113694039B (en) | Pellet for tonifying qi and benefiting blood and preparation method thereof | |
| CN106620367A (en) | Traditional Chinese medicine sustained-release capsule for treating cystolith and preparation method thereof | |
| CN107213323B (en) | Chinese medicinal compound preparation for nourishing yin, eliminating phlegm, resolving masses and detoxifying and application thereof | |
| CN103784848A (en) | Traditional Chinese medicinal composition for treating chronic colitis and preparation and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230427 Address after: 215100 C30, bio nano technology park, 218 Xinghu street, Suzhou Industrial Park, Jiangsu Province Patentee after: SUZHOU YOUSEEN NEW DRUG R & D Co.,Ltd. Address before: 200127 No. 270, Dong'an Road, Xuhui District, Shanghai Patentee before: FUNDAN University SHANGHAI CANCER CENTER |
|
| TR01 | Transfer of patent right |